Hikma Expansion (IFC-37324)

  • Middle East and North Africa
Where the impacts of the investment may be experienced.
  • Jordan
Where the impacts of the investment may be experienced.
Financial Institutions
  • International Finance Corporation (IFC)
International, regional and national development finance institutions. Many of these banks have a public interest mission, such as poverty reduction.
Project Status
Bank Risk Rating
Risk rating varies among banks and may refer only to the particular investment and not to the risk for the project as a whole. Projects marked 'U' have an 'Unknown' risk rating at the time of disclosure.
Voting Date
Jun 9, 2017
The estimate day the bank will vote on a proposed investment. The decision dates may change, so review updated project documents or contact the EWS team.
The holder of the loan, grant, or other investment.
  • Education and Health
The service or industry focus of the investment. A project can have several sectors.
Investment Type(s)
The categories of the bank investment: loan, grant, etc.
Investment Amount (USD)
$ 150.00 million
Value listed on project documents at time of disclosure. If necessary, converted to USD$. Please review updated project documents for more information.
Project Cost (USD)
$ 150.00 million
Value listed on project documents at time of disclosure. If necessary, converted to USD$. Please see updated project documentation for more information.
Primary Source

Original disclosure @ IFC website

Updated in EWS Mar 1, 2018

Disclosed by Bank Dec 21, 2017

Contribute Information
Can you contribute information about this project?
Contact the EWS Team

Project Description

Hikma Pharmaceuticals invited IFC to provide and arrange financing to support the general corporate purposes of the Company and members of its Group in the MENA region and/or in other World Bank Group countries of operation. Demonstration Effect: Hikma will bring in high quality manufacturing in emerging markets.

Investment Description
Private Actors Description

Hikma Pharmaceuticals PLC (“Hikma” or the “Company”) and its subsidiaries (the “Group”), is a generic pharmaceutical company incorporated in United Kingdom(“UK”)and listed on the London Stock Exchange (“LSE”). While the Group was founded in Jordan in 1978, Hikma has expanded its footprint with successful operations across the Middle East and North Africa (“MENA”) region, the United States (“US”) and Europe. The Company has 29 manufacturing facilities in 11 countries out of which facilities in 5 countries have received US Food and Drug Administration (“FDA”) approval. Hikma’s main business lines include branded, injectables and generic pharmaceuticals. Hikma is a long-standing IFC client since 1987.

Private Actor 1 Private Actor 1 Role Private Actor 1 Sector Relation Private Actor 2 Private Actor 2 Role Private Actor 2 Sector
- - - - Hikma Pharmaceuticals PLC Client -

Contact Information

Hikma Pharmaceuticals PLC
Ibrahim Armouti
Group Treasurer
+962 6 5802900
P.O. Box: 182400, Amman 11118, Jordan



The Compliance Advisor Ombudsman (CAO) is the independent complaint mechanism and fact-finding body for people who believe they are likely to be, or have been, adversely affected by an IFC or MIGA- financed project. If you submit a complaint to the CAO, they may assist you in resolving a dispute with the company and/or investigate to assess whether the IFC is following its own policies and procedures for preventing harm to people or the environment. If you want to submit a complaint electronically, you can email the CAO at CAO@worldbankgroup.org. You can learn more about the CAO and how to file a complaint at http://www.cao-ombudsman.org/